CRIS Current Research Information System

BISELLI, MAURIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.238
AS - Asia 3.472
EU - Europa 3.460
AF - Africa 295
SA - Sud America 208
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 4
Totale 12.683
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.207
SG - Singapore 1.122
CN - Cina 928
GB - Regno Unito 718
VN - Vietnam 696
IT - Italia 662
SE - Svezia 505
DE - Germania 450
HK - Hong Kong 248
IN - India 214
RU - Federazione Russa 159
NL - Olanda 148
BR - Brasile 147
IE - Irlanda 145
FR - Francia 142
UA - Ucraina 127
CH - Svizzera 116
TG - Togo 100
JO - Giordania 80
FI - Finlandia 68
CI - Costa d'Avorio 67
ZA - Sudafrica 65
KR - Corea 59
EE - Estonia 53
BG - Bulgaria 46
JP - Giappone 37
SC - Seychelles 29
BE - Belgio 25
IR - Iran 23
AT - Austria 22
NG - Nigeria 19
AR - Argentina 18
CA - Canada 17
EC - Ecuador 17
ID - Indonesia 16
PL - Polonia 15
ES - Italia 14
HR - Croazia 13
CL - Cile 11
MX - Messico 9
BD - Bangladesh 8
AU - Australia 6
CO - Colombia 5
LB - Libano 5
LT - Lituania 5
MA - Marocco 5
UZ - Uzbekistan 5
CZ - Repubblica Ceca 4
DK - Danimarca 4
PK - Pakistan 4
PT - Portogallo 4
RO - Romania 4
TH - Thailandia 4
AE - Emirati Arabi Uniti 3
GR - Grecia 3
IQ - Iraq 3
MK - Macedonia 3
PY - Paraguay 3
TR - Turchia 3
CR - Costa Rica 2
EG - Egitto 2
ET - Etiopia 2
EU - Europa 2
IL - Israele 2
MM - Myanmar 2
MY - Malesia 2
PH - Filippine 2
SA - Arabia Saudita 2
SN - Senegal 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
VE - Venezuela 2
XK - ???statistics.table.value.countryCode.XK??? 2
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
DZ - Algeria 1
FK - Isole Falkland (Malvinas) 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LV - Lettonia 1
MU - Mauritius 1
NO - Norvegia 1
PE - Perù 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
TW - Taiwan 1
YE - Yemen 1
Totale 12.683
Salva come PNG Salva come JPEG
Città #
Singapore 740
Southend 628
Fairfield 590
Ashburn 585
Chandler 510
Dong Ket 415
Woodbridge 286
Houston 275
Seattle 263
Hong Kong 248
Bologna 236
Wilmington 223
Cambridge 208
Santa Clara 179
Princeton 172
Ann Arbor 154
Hefei 152
Dublin 144
Beijing 122
Boardman 111
Bern 105
Lomé 100
Amman 80
Jacksonville 78
Ho Chi Minh City 73
Dallas 72
Redmond 70
Abidjan 67
Westminster 66
Los Angeles 61
Padova 57
Seoul 57
Berlin 55
Hanoi 53
Nanjing 51
Helsinki 50
New York 48
Shenyang 43
Sofia 43
Milan 42
Munich 41
Jinan 39
Buffalo 37
San Diego 36
Tokyo 36
Florence 34
Saint Petersburg 31
Turin 31
Redondo Beach 26
Bremen 25
Brussels 25
Falkenstein 23
Nanchang 23
Tianjin 23
Hebei 22
Rome 22
Abeokuta 19
Changsha 19
Amsterdam 18
Des Moines 18
Frankfurt am Main 18
Guangzhou 18
London 17
São Paulo 17
Hangzhou 16
Medford 16
Phoenix 16
Chicago 15
Mülheim 15
Shanghai 15
Vienna 15
Dearborn 14
Paris 14
Zhengzhou 14
Bengaluru 13
Norwalk 13
Washington 13
Wuhan 13
Brooklyn 12
Falls Church 12
Jiaxing 12
Olalla 12
Turku 12
Mahé 11
Orem 10
Redwood City 10
San Francisco 10
Yubileyny 10
Düsseldorf 9
Fort Worth 9
Haiphong 9
Rio de Janeiro 9
San Jose 9
Warsaw 9
Ardabil 8
Guayaquil 8
Ningbo 8
Charlotte 7
Delhi 7
Hyderabad 7
Totale 8.542
Salva come PNG Salva come JPEG
Nome #
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 266
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 240
Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. 230
Albumin homodimers in patients with cirrhosis: clinical and prognostic relevance of a novel identified structural alteration of the molecule. 219
Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. 216
Acquired intestinal lymphangiectasia successfully treated with a low fat and MCT-enriched diet in a patient with liver transplantation. 208
A new prognostic model to predict drop-out from the waiting list in cirrhotic candidates for liver transplantation wirh MELD score <18. 204
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 204
Allocation priority in non urgent liver transplantation: an overview of proposed scoring systems 196
BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. 194
Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma 194
Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial 193
Application of the Intermediate-Stage Subclassification to Patients with Untreated Hepatocellular Carcinoma 193
Monofocal hepatocellular carcinoma: How much does size matter? 190
Optimization of pineapple juice amount used as a negative oral contrast agent in magnetic resonance cholangiopancreatography 186
Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatments and outcome. 184
Alcoholic liver disease: pathophisiological aspects and risk factors. A review. 182
Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. 180
Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen. 178
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. 177
Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma 176
Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA. database 174
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 173
An in-depth psychosocial and biochemical evaluation in transplant recipients for alcoholic liver disease should be planned. 170
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 168
Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients 166
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. 166
null 164
Metabolic disorders across hepatocellular carcinoma in Italy 164
Prognostic Role of Bacterial and Fungal Infections in Patients with Liver Cirrhosis with and without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study 160
High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing Lamivudine resistance. 159
Pattern of macrovascular invasion in hepatocellular carcinoma 159
Liver transplantation for patients with alcoholic liver disease: an open question 158
What is the best fruit juice to use as a negative oral contrast agent in magnetic resonance cholangiopancreatography? 157
New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: A new diagnostic algorithm 156
Chronic prostatitis/pelvic pain syndrome: MRI findings and clinical correlations. 156
Biomarkers for the early diagnosis of bacterial infection and the surveillance of hepatocellular carcinoma in cirrhosis 155
Posttranscriptional changes of serum albumin: clinical and prognostic meaning in hospitalized patients with cirrhosis. 155
Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft 154
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 154
Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin 152
Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. 148
High incidence of allograft dysfunction in liver transplant patients treated with PEG-Interferon alfa-2b and Ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? 146
QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. 143
Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. 143
In vitro effect of indomethacin and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C 143
Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma 139
Trattamento dell’epatopatia alcolica 137
Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib 135
Authors’ reply: Comment to “Liver transplantation for patients with alcoholic liver disease: An open question” 135
Two years Mycophenolate Mofetil plus low dose calcineurin inhibitor for renal dysfunction after liver transplantation. 135
Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case controlled study 134
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of non-responder patients with chronic hepatitic C. 133
Years of life that could be saved from prevention of hepatocellular carcinoma. 133
Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: which is the winner? 133
Development and validation of a scoring system that includes corrected QT interval for risk analysis of patients with cirrhosis and gastrointestinal bleeding 131
The MELD score in patients awaiting liver transplant: strengths and weaknesses. 127
Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score Analysis 126
Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? 125
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 122
GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) ADMINISTRATION IN CIRRHOTIC PATIENTS: A PHASE II STUDY EVALUATING TOLERABILITY PROFILE AND MOBILIZATION OF HAEMATOPOIETIC STEM CELLS (HSCS). 121
Magnetic Resonance Enterography Reinvented: Exploring the Potential of a New Natural Beverage as an Alternative to Polyethylene Glycol Solution 119
New MRI series for kidney evaluation: Saving time and money 118
The Gastropack Access System as a Model to Access Gastroenterology Services for Gastroscopy Appropriateness in Patients with Upper Gastrointestinal Symptoms: A Comparison with the Open Access System 117
Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study 117
null 117
The changing scenario of hepatocellular carcinoma in Italy: an update 112
The evolutionary scenario of hepatocellular carcinoma in Italy: an update. 112
Hepatic artery stenosis in liver transplanted patients treated with pegylated Interferon alpha-2b and Ribavirin 110
OUTCOME OF LIVER TRANSPLANT FOR ALCOHOLIC LIVER DISEASE. 110
Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. 108
PEGYLATED INTERFERON PLUS RIBAVIRIN FOR THE TREATMENT OF RECURRENT HCV INFECTION AFTER LIVER TRANSPLANTATION 106
Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicentre experience in Italy. 99
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma 97
Hepatocellular carcinoma surveillance: an open question 97
null 95
Liver injury with novel oral anticoagulants: Assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system 90
Sustained and focused HBV-nucleocapsid-specific T cell immunity in liver transplant recipients compared to individuals with chronic and self-limited HBV infection. 90
OUTCOME OF LIVER TRANSPLANT FOR ALCOHOLIC LIVER DISEASE 87
null 83
Hierarchically Positioning Laparoscopic Microwave Ablation in the Therapeutic Span of Early Hepatocellular Carcinoma: A Real-Life Comparative Analysis 82
Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival 75
null 72
Reply to “Re: Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma—A Propensity Analysis” 70
Hepatitis C virus reinfection after liver transplantation: is there a role for direct antiviral agents? 60
A modified Child-Turcotte-Pugh (CTP) for selection of candidates to liver transplantation (LT) with low model for end-stage liver disease score (MELD). 60
Increased survival after sustained virological response in liver transplanted patients with HCV recurrence: taking-up a challenge for the hepatologist. 59
Increased survival after sustained virological response in liver transplanted patients with HCV recurrence: taking-up a challenge for the hepatologist. 58
A modified Child-Turcotte-Pugh (CTP) for selection of patients affected by cirrhosis candidates for liver transplantation (LT) with low model for end-stage liver disease score (MELD) 58
Prognosis of untreated hepatocellular carcinoma. 49
Seven score systems to evaluate candidates to orthotopic liver transplantation: which is the winner? 46
Natremia and Child-Turcotte-Pugh (CTP) score may improve the selection of candidates for liver transplantation (LT) with lower model for end-stage liver disease score (MELD) 43
Natremia and Child-Turcotte-Pugh (CTP) may improve the selection of candidates for liver transplantation (LT) with lower model for end-stage liver disease score (MELD). 42
Outcome of hepatic resection for HCC in ideal and non-ideal candidates 30
Totale 12.907
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.623
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.623
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021962 0 0 0 0 0 60 35 51 110 72 63 571
2021/20221.849 133 83 81 153 138 101 45 145 66 145 491 268
2022/20232.136 194 338 99 286 113 179 79 105 360 66 160 157
2023/2024621 64 87 45 50 48 131 21 61 28 31 35 20
2024/20252.016 80 286 179 179 277 110 192 71 15 175 97 355
2025/20262.224 362 370 412 314 491 275 0 0 0 0 0 0
Totale 12.907